Cell:剑桥革命性新技术能更快筛选抗癌药物并公开数据

2016-09-26 佚名 生物探索

导语:根据9月22日发表在Cell上,英国癌症研究基金支持的一项研究文章报道:剑桥大学的科学家发现了一项新技术,可以很快地测试数百种抗癌药物,大大减少发现潜在的乳腺癌治疗方法的时间。他们向全球公开此项技术的数据。剑桥大学的科学家发现检测药物的新方法,可以加快乳腺癌治疗手段的发展。根据9月22日发表在Cell上,英国癌症研究基金支持的一项研究文章报道:这项新技术可以很快地测试数百种抗癌药物,大大减少

导语:根据9月22日发表在Cell上,英国癌症研究基金支持的一项研究文章报道:剑桥大学的科学家发现了一项新技术,可以很快地测试数百种抗癌药物,大大减少发现潜在的乳腺癌治疗方法的时间。他们向全球公开此项技术的数据。

剑桥大学的科学家发现检测药物的新方法,可以加快乳腺癌治疗手段的发展。根据9月22日发表在Cell上,英国癌症研究基金支持的一项研究文章报道:这项新技术可以很快地测试数百种抗癌药物,大大减少发现潜在的乳腺癌治疗方法的时间。

研究人员先在小鼠体内培养人乳腺癌细胞,再用实验药物进行进一步的测试。

以这种方式生长的细胞更能准确地模拟人身体中的癌细胞生长,并更接近地反映出在患者的癌细胞中发现的基因缺陷。这种方法意味着更多的药物可以在相同的时间以不同的组合进行测试,可能缩短为患者提供新的药物所需的时间。



该项目新的研究方法减少了试验中使用的小鼠数量,同时使药物测试更加准确。这种新技术意味着研究人员从小鼠体内将癌细胞再转移出来后,可以进行数百种药物的试验。此项技术将取代目前在塑料培养皿中培养癌细胞的然后再在小鼠身上测试的实践。目前的方法的局限性在于肿瘤细胞在塑料培养皿中的生长是异于在身体中的。

英国癌症研究中心剑桥研究所所长、剑桥乳腺癌研究的领导者,通讯作者Carlos Caldas教授说:“传统上我们都在培养基中培养细胞,但这是人工的,因为在体内细胞以更负责的方式生长。在将来,这种新技术,和他人一样,将取代实验室中今天使用的方法。”

Carlos Caldas教授介绍:“我们正在做的是将我们所有的数据公开,世界各地的其它研究人员可以使用和收益于我们的工作,我们会继续改进它。”

英国癌症研究中心的高级科学信息经理Nell Barrie说:“寻找更准确和有效的新方法来检测对抗癌症的潜在药物是非常重要的。这样的研究可以帮助我们更快地找到新的治疗方法,也有助于确定特定患者群体的药物的最佳组合,以确保更多的人能从疾病中生存下来。”

原始出处:

Bruna A1, Rueda OM1, Greenwood W1, Batra AS1, Callari M1, Batra RN1, Pogrebniak K1, Sandoval J1, Cassidy JW1, Tufegdzic-Vidakovic A1, Sammut SJ1, Jones L2, Provenzano E3, Baird R2, Eirew P4, Hadfield J1, Eldridge M1, McLaren-Douglas A5, Barthorpe A5, Lightfoot H5, O'Connor MJ6, Gray J7, Cortes J8, Baselga J9, Marangoni E10, Welm AL11, Aparicio S4, Serra V8, Garnett MJ5, Caldas C12.A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.Cell. 2016 Sep 22

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869563, encodeId=f75a18695630a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 29 02:04:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903726, encodeId=9b591903e26ec, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Thu Jun 08 19:04:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959822, encodeId=8b50195982276, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 22 04:04:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138846, encodeId=fc5813884651, content=很好,很有帮助,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Sun Oct 02 10:32:49 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308224, encodeId=c4e0130822486, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314678, encodeId=9d9713146e8d9, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584358, encodeId=d3c7158435893, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135858, encodeId=d88f13585837, content=以后多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160927/IMG57EA05AC632186996.jpg, createdBy=cb591958173, createdName=医者自医, createdTime=Tue Sep 27 13:05:08 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869563, encodeId=f75a18695630a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 29 02:04:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903726, encodeId=9b591903e26ec, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Thu Jun 08 19:04:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959822, encodeId=8b50195982276, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 22 04:04:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138846, encodeId=fc5813884651, content=很好,很有帮助,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Sun Oct 02 10:32:49 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308224, encodeId=c4e0130822486, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314678, encodeId=9d9713146e8d9, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584358, encodeId=d3c7158435893, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135858, encodeId=d88f13585837, content=以后多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160927/IMG57EA05AC632186996.jpg, createdBy=cb591958173, createdName=医者自医, createdTime=Tue Sep 27 13:05:08 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869563, encodeId=f75a18695630a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 29 02:04:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903726, encodeId=9b591903e26ec, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Thu Jun 08 19:04:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959822, encodeId=8b50195982276, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 22 04:04:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138846, encodeId=fc5813884651, content=很好,很有帮助,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Sun Oct 02 10:32:49 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308224, encodeId=c4e0130822486, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314678, encodeId=9d9713146e8d9, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584358, encodeId=d3c7158435893, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135858, encodeId=d88f13585837, content=以后多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160927/IMG57EA05AC632186996.jpg, createdBy=cb591958173, createdName=医者自医, createdTime=Tue Sep 27 13:05:08 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
    2017-02-22 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1869563, encodeId=f75a18695630a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 29 02:04:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903726, encodeId=9b591903e26ec, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Thu Jun 08 19:04:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959822, encodeId=8b50195982276, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 22 04:04:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138846, encodeId=fc5813884651, content=很好,很有帮助,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Sun Oct 02 10:32:49 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308224, encodeId=c4e0130822486, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314678, encodeId=9d9713146e8d9, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584358, encodeId=d3c7158435893, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135858, encodeId=d88f13585837, content=以后多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160927/IMG57EA05AC632186996.jpg, createdBy=cb591958173, createdName=医者自医, createdTime=Tue Sep 27 13:05:08 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
    2016-10-02 右脚梅西

    很好,很有帮助,谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1869563, encodeId=f75a18695630a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 29 02:04:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903726, encodeId=9b591903e26ec, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Thu Jun 08 19:04:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959822, encodeId=8b50195982276, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 22 04:04:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138846, encodeId=fc5813884651, content=很好,很有帮助,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Sun Oct 02 10:32:49 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308224, encodeId=c4e0130822486, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314678, encodeId=9d9713146e8d9, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584358, encodeId=d3c7158435893, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135858, encodeId=d88f13585837, content=以后多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160927/IMG57EA05AC632186996.jpg, createdBy=cb591958173, createdName=医者自医, createdTime=Tue Sep 27 13:05:08 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1869563, encodeId=f75a18695630a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 29 02:04:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903726, encodeId=9b591903e26ec, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Thu Jun 08 19:04:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959822, encodeId=8b50195982276, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 22 04:04:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138846, encodeId=fc5813884651, content=很好,很有帮助,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Sun Oct 02 10:32:49 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308224, encodeId=c4e0130822486, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314678, encodeId=9d9713146e8d9, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584358, encodeId=d3c7158435893, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135858, encodeId=d88f13585837, content=以后多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160927/IMG57EA05AC632186996.jpg, createdBy=cb591958173, createdName=医者自医, createdTime=Tue Sep 27 13:05:08 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
    2016-09-28 sunylz
  7. [GetPortalCommentsPageByObjectIdResponse(id=1869563, encodeId=f75a18695630a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 29 02:04:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903726, encodeId=9b591903e26ec, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Thu Jun 08 19:04:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959822, encodeId=8b50195982276, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 22 04:04:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138846, encodeId=fc5813884651, content=很好,很有帮助,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Sun Oct 02 10:32:49 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308224, encodeId=c4e0130822486, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314678, encodeId=9d9713146e8d9, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584358, encodeId=d3c7158435893, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135858, encodeId=d88f13585837, content=以后多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160927/IMG57EA05AC632186996.jpg, createdBy=cb591958173, createdName=医者自医, createdTime=Tue Sep 27 13:05:08 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1869563, encodeId=f75a18695630a, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Tue Nov 29 02:04:00 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903726, encodeId=9b591903e26ec, content=<a href='/topic/show?id=be285836438' target=_blank style='color:#2F92EE;'>#新技术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58364, encryptionId=be285836438, topicName=新技术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d39f177, createdName=lixiao3326, createdTime=Thu Jun 08 19:04:00 CST 2017, time=2017-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959822, encodeId=8b50195982276, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Feb 22 04:04:00 CST 2017, time=2017-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138846, encodeId=fc5813884651, content=很好,很有帮助,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160930/IMG57EDFF4739EBF3035.jpg, createdBy=0da11618734, createdName=右脚梅西, createdTime=Sun Oct 02 10:32:49 CST 2016, time=2016-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308224, encodeId=c4e0130822486, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314678, encodeId=9d9713146e8d9, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584358, encodeId=d3c7158435893, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Wed Sep 28 00:04:00 CST 2016, time=2016-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=135858, encodeId=d88f13585837, content=以后多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160927/IMG57EA05AC632186996.jpg, createdBy=cb591958173, createdName=医者自医, createdTime=Tue Sep 27 13:05:08 CST 2016, time=2016-09-27, status=1, ipAttribution=)]
    2016-09-27 医者自医

    以后多学习

    0

相关资讯

微软放下豪言:10年之内解决癌症问题

据外媒报道,微软公司近日对外宣布,他们希望在10年之内利用计算机科学解决癌症问题。微软的这项计划最令人惊喜的是,他们将研制出小型DNA计算机,并让这些计算机进入人体来解决癌症问题。在体内成功运行后,计算机将监视癌细胞并且重新编码这些癌细胞,让癌细胞转化为健康细胞。为了实现这项伟大的计划,微软将在计算机领域和癌症领域广泛招揽人才,来保证这种计算机顺利研制成功。目前微软的研究计划还没有正式确定,不过机

Cell揭秘:癌细胞如何对抗“免疫疗法”?靠突变! 大牛夫妇新作

Cell揭秘:导语:德克萨斯大学安德森癌症中心免疫学系主任James P.Allison教授是癌症免疫疗法的先驱之一,也被称CTLA-4抗体“Yervoy之父”。这款在2011年获FDA批准的免疫疗法抗体挽救了无数癌症患者的生命。9月21日,Allison教授荣获了有着诺奖风向标之称的汤森路透“引文桂冠奖”。相隔1天,这位大牛又在Cell杂志上发表了一项重要成果,揭秘了癌细胞对抗免疫疗法的关键

盘点:精准医疗助推癌症的治愈

最新一期《福布斯》展望了未来15年影响世界的五大技术——新型计算机架构、基因组学、纳米技术、储能技术以及机器人技术。文章说,随着这些技术相辅相成,共同发展,人类将开始掌控物理世界。其中关于“基因组学”的解释为:2003年人类基因组首次被解码,其相关开支超过30亿美元。到2030年,人类基因组测序技术将日趋完善,成本也将低于100美元。目前,人类已经将基因组学应用于癌症治疗等医疗领域,通

地中海饮食习惯 可延缓老年人认知衰退

导语:地中海饮食被认为是一种健康的饮食习惯,它可以减少心血管疾病和癌症风险。近日,一项研究表明这种饮食或许还能够减缓老年人的认知衰退的过程。地中海饮食——由丰富的蔬菜,鱼肉和橄榄油组成,调节酒精消耗,已经被证明可以减少心脏病、某些癌症和糖尿病的风险。一项研究表明这种饮食或许还能够减缓老年人的认知衰退的过程。这项研究发表于近日的American Journal of Clinical Nutriti

15块钱小苏打治肝癌,什么情况?

昨天,一则某大众媒体的医学报道突然火了——真是这么回事吗?让我们来看看原研究怎么说的吧……先上个论文摘要由于这次媒体报道实在太玄乎,咱们还是来看看朴实无华的原文摘要,先来搞清一下是怎么回事。首先呢作者说因为之前的其他研究有提示中和肿瘤内如酸中毒和葡萄糖剥夺联合起来可以产生控制肿瘤的效果。所以他们进行了两个临床试验,一个是随机的(样本为20名大肝癌患者),另一个不是(样本为57名大肝癌患者)。采取的

JCI:新研究为癌症“广谱”治疗找到方向

最近,国际学术期刊JCI在线发表了新加坡分子细胞生物学研究所的一项最新研究进展,他们发现端粒酶逆转录酶能够通过促进tRNA表达,增强细胞整体蛋白质翻译过程,促进癌细胞增殖。该研究为癌症治疗药物开发提供了重要方向。 在多数人类癌症中端粒酶逆转录酶(TERT)的重新激活会导致端粒酶活性得到还原。而在这项研究中,研究人员发现虽然TERT的异常表达会促进细胞增殖,TERT水平的急性减少也会导致细